Abstract
The pathbreaking discovery of sotorasib as KRAS G12C inhibitor has revolutionized the prognostic outcome of KRAS mutated metastatic NSCLC. This is a single centre experience of KRAS mutated NSCLC in an Indian cohort, underscoring the unmet urgent need of sotorasib in this part of the world.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
